MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12072-019-09982-z

Медицинская библиотека · Hepatology international · 2019

Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis.

Wang Qianyi, You Hong, Ou Xiaojuan, Zhao Xinyan, Sun Yameng, Wang Min, Wang Ping, Wang Yu, Duan Weijia, Wang Xiaoming, Wu Shanshan, Kong Yuanyuan, Saxena Romil, Gouw Annette S H, Jia Jidong

СтатьяПеревод в очереди

Аннотация

BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) commonly affects subjects with obesity, yet non-obese NAFLD is increasingly being recognized. We aimed to investigate the clinicopathological and genetic characteristics of non-obese NAFLD patients.

METHODS

The clinical, histological and genetic data of 84 NAFLD patients with biopsy for abnormal liver function test were reviewed. Both NAS-CRN and SAF scoring systems were applied for histopathological evaluation. PNPLA3 and TMS6F2 genotyping were also performed.

RESULTS

All of the 84 patients were histologically diagnosed with non-alcoholic steatohepatitis (NASH), with 36 of them (42.9%) being non-obese (BMI < 25 kg/m2). Compared with the obese group, non-obese group were predominantly females (88.9% vs 52.1%, p < 0.001), tended to have higher prevalence of diabetes (p = 0.068). More importantly non-obese patients had a significant higher prevalence of advanced fibrosis (F ≥ 3) (58.3% vs 29.2%, p = 0.013), and a trend of higher degree of ballooning (p = 0.061). In addition, values of liver stiffness measurement were also significantly higher in non-obese group (12.1 kPa vs 8.1 kPa, p = 0.032). There was also a trend of higher prevalence of TM6SF2 T allele in non-obese group (p = 0.085), while the prevalence of PNPLA3 risk allele did not differ between two groups. Multivariate analysis showed that higher fasting glucose (p = 0.038) and lower serum platelets (p = 0.040) were two independent predictors for advanced fibrosis in non-obese patients.

CONCLUSIONS

Non-obese NASH patients have a female predominance and more advanced fibrosis. Liver biopsy is crucial to evaluate the severity of disease in non-obese patients especially those with abnormal liver biochemistry.

CLINICAL TRIAL NUMBER: NCT03386890.

Для цитирования: Wang Qianyi, You Hong, Ou Xiaojuan, Zhao Xinyan, Sun Yameng, Wang Min, Wang Ping, Wang Yu, Duan Weijia, Wang Xiaoming, Wu Shanshan, Kong Yuanyuan, Saxena Romil, Gouw Annette S H, Jia Jidong. Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis.. Hepatology international. 2019. DOI: 10.1007/s12072-019-09982-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.